This review touches on the historical links between epilepsy, seizures and the uterus and ovaries which have fascinated and misled physicians since Greco-Roman times. It then examines present knowledge of ovarian function and its effect on epileptic activity and vice versa before exploring the modern controversy about polycystic ovaries and the polycystic ovary syndrome, epilepsy and anticonvulsant medication. Based on present evidence, women with epilepsy are more prone to develop polycystic (polyfollicular) ovaries than other women due to the epilepsy itself. But women with epilepsy related polycystic (polyfollicular) ovaries are vulnerable to the effects of sodium valproate (possibly particularly during adolescence) and may develop the polycystic ovary syndrome: this is reversible if the valproate is withdrawn. Lamotrigine and carbamazepine seem to prevent the development of the syndrome.
INTRODUCTION
'Into her womb convey sterility.
Dry up in her the organs of increase'
Shakespeare, King Lear.
The female organs of reproduction, initially the uterus and later the ovary, have been long connected in the (usually male) medical mind with seizures, whether non-epileptic or the genuine article. There was a Greco-Roman belief, said to be found in the writings of Hippocrates and later expounded by Galen, that seizures in women were caused by the uterus moving from its proper place, rising from the pelvis into the abdomen, sometimes into the thoracic cavity and causing symptoms of ' smothering' which included convulsive behaviour. When these ancient writings were 'rediscovered' from the 14th century onwards, this gynaecentric idea became elaborated to include both seizures themselves plus a whole host of anxiety based symptoms eventually going under the rubric of 'hysteria' (related to hystera, the Greek word for the womb). The terms 'suffocation of the mother' or 'fits of the mother' (the mother being the uterus) were in widespread use in the 16th and 17th centuries with some attempt to separate these symptoms from epilepsy itself. We still find some echoes of these terms and ideas in our own day. We still use the term 'globus hystericus' to describe the anxiety symptom of a lump in the throat and difficulty in swallowing, although the term hysteria is now obsolete. Victorian ladies, culturally addicted to swooning, were made to inhale sal volate (ammonia) much as people with epilepsy, from ancient times, were made to inhale burning hartshorn. There was a longstanding belief that similar disorders did not exist in men who, fairly obviously, lack a uterus. Shakespeare was slightly before his time using the term 'hysterico passio' in a male context although, as has been demonstrated, there were other reasons for his use of this term 1 .
The remedy for uterine perambulation was designed to drive the errant organ back to its proper place. This included getting the patient to inhale unpleasant or noxious fumes to drive the womb away from the chest and, sometimes, the placing of sweet smelling substances into the vagina to encourage rapid return of the uterus (it seems that this was more likely to be used if the physician felt that the seizures so treated were of a non-epileptic nature). Such treatment was certainly still in use in England in the early 17th century 2 . The long held belief that the uterus was responsible for neurological symptoms may, in part, have been due to a mistranslation of the original Hippocratic writings, which were actually a gynaecological text 3 . In mediaeval times this rather absurd belief was perpetuated by academic authoritarianism which prevented rational discussion of the ancient's ideas; very much in the same way as the Galenic practice of bleeding (which he seems to have developed from noticing that natural menstruation in women seemed to relieve certain symptoms) continued for hundreds of years despite what must have been obvious evidence that it was not only futile but dangerous (particularly on the battlefield). Luckily for women the other Greco-Roman medical belief that therapeutic sexual intercourse cured these uterine-based neurological problems seems to have died out quite early on.
Perhaps it was also lucky for women that the structure of the ovary was not fully described (except in animals) until the 16th century by Vesalius and his pupils in Padua. The function of the ovary was not fully recognized until the 18th and 19th centuries. In the 19th century gynaecological surgeons discovered the apparent importance of the ovary in the causation of epilepsy in women. From the mid 19th century onwards they began to remove ovaries to cure epilepsy (this may have been triggered by the recognition of the waxing and waning of seizure frequency during the menstrual cycle). Indeed the view was expounded that 'gynaecology represents the bridge between general medicine and neuropathology' 4 . Battey's operation (female castration) became a very popular treatment for epilepsy (and other neuropsychiatric symptoms) in young women. It persisted in use into the early part of the 20th century, despite a heavy mortality rate. (Male castration for epilepsy was little practised, although bromide treatment for epilepsy was introduced in the belief that excessive sexuality and masturbation caused epilepsy in men.) Luckily Battey's operation eventually disappeared though controversy continues up to the present day about whether or not menstrual cycle related epilepsy exists 5 : the consensus view is that it does. Interest in other possible gynaecological relationships with epilepsy has also persisted. There is still a quaint gynaecological belief that removing the ovaries will 'cure' premenstrual seizures, ignoring the fact that menstrual cycling and epilepsy are initiated in the brain and not in the pelvis. Ovariectomy in a premenopausal woman, however, leads to an acute menopause, which has to be treated with depot hormone replacement therapy, which can lead to significant seizure increase if the woman has epilepsy.
There is evidence (reviewed by Herzog 1997) 6 , that women with epilepsy, whether or not they are taking antiepileptic drugs, are more likely to have anovulatory cycles, polycystic ovaries and possibly the polycystic ovary syndrome (PCOS). This is attributed to changes in gonadtropic hormone synthesis and release in the mid brain caused by recurrent epileptic discharges in the same area 6 .
Interest in the endocrine effects of seizure discharge on ovarian function, lukewarm at best, rapidly intensified following the publication in 1993 of a paper by Isojärvi and his colleagues 7 which suggested that the increased incidence of the PCOS in women with epilepsy was due to sodium valproate. This paper was followed by others 8, 9 which confirmed the original findings, suggested that valproate might cause this syndrome by increasing insulin resistance (with an associated rise in serum insulin levels): insulin resistance is known to be associated with the PCOS. It was suggested that removal of valproate and substitution of lamotrigine caused the PCOS to regress.
These papers, unfortunately, (even though they are flawed as will be described later) became the pivot of a controversy about the relative merits of valproate and lamotrigine, the manufacturers of lamotrigine wishing to show that for women their product was superior since it appeared not to induce the PCOS: the manufacturers of valproate obviously resisted this idea. This lead to clinicians taking sides before they had had a chance of reading the controversial papers thoroughly or developing an understanding of the possible causes of polycystic ovaries and the PCOS. Unfortunately this area is a minefield as ideas about polycystic ovaries and the PCOS are undergoing a significant change. To understand something of the possible relationship between epilepsy, its treatment and the ovary it is necessary to have an understanding of the structure and function of the ovary, and the nature of both polycystic ovaries and the syndrome itself.
The ovary: from indifferent gonad to egg and endocrine factory For a full review of the embryology, structure, function and dysfunction of the ovary see the relevant chapters in Speroff, Glass and Kase 1999 10 . Initially, when the ovary first develops as the gonadal ridge in early embryonic life it is undifferentiated (the indifferent gonad) and has the potential to be either testis or ovary. By the sixth to ninth week of intrauterine life differentiation into ovarian tissue begins. Germ cells multiply into oocytes: there are six to seven million by 16-20 weeks of embryonic life (this number falls to about two million at birth and perhaps 400 000 by puberty). After puberty many oocytes will develop into follicles part way toward ovulation: but only 400-500 will be 'chosen' for ovulation: the rest, having advanced a little way in the process will decline and disappear ('atretic follicles'): for every follicle that develops into ovulation, nearly 1000 will become atretic. It takes about 85 days for a primordial follicle to develop to ovulation. Maturity needs follicle stimulating hormone (FSH) activity, but other factors are involved: rupture of the follicle at the appropriate time is dependant on a prostaglandin synthesis surge within the follicle; the midcycle gonadotrophic surge may also help this process, which, if prevented, leads to a corpus luteum with a trapped oocyte.
Thus scanning of the ovary at a point in time will reveal developing follicles, one or two preovulatory (Graafian) follicles, possibly a recently ruptured follicle and atretic follicles. After release of the egg, the corpus luteum develops: it persists if the egg is fertilized, but if it is not the corpus luteum degenerates into the corpus albicans and disappears: menstruation occurs and the egg or its remains washed out on the menstrual tide as the cycle begins again. The process of selection of successful follicles and the apoptosis of unsuccessful atretic follicles depends on complex factors: follicles at a critical stage of development respond to FSH stimulation with the development of an oestrogen microenvironment which promotes further development: but oestrogen release inhibits FSH production: the decline in FSH release inhibits further growth of the less mature follicles. Apoptosis occurs when unsuccessful follicles begin to secrete tumour necrosis factor (TNF) which inhibits oestrogen production in the follicle mediated by FSH. Increasing levels of TNF hasten the physiological death of the follicle.
Corpus luteum development is initiated by the midcycle release of luteinizing hormone (LH) with FSH. This midcycle surge is responsible for inhibition of oestrogen production at midcycle (with a subsequent rise prior to menstruation) and increases progesterone production in the ovary. LH increases testosterone production in the ovary as well. Testosterone is converted into oestrogen within the follicle: but too much testosterone overwhelms this mechanism and renders the follicle atretic. Insulin-like growth factor (ILGF) is also important in modulating this process: a rise in plasma insulin may, therefore, affect it.
The ovary is therefore not only a factory for the production of eggs for fertilization, but a complex endocrine organ as well: it has been said 'the complex events that yield an ovum for fertilization and ovarian structures that provide hormonal support are the products of essentially every regulating mechanism in human biology 10 '. Changes in gonadotrophic secretion can have profound effects on ovarian homeostasis and hormone production: this is a two way relationship. Hormone production in the ovary is from the cells that line the follicles and from the stroma itself, which is particularly the site of androgen production: human and primate stroma has autonomic nervous system innervation (not found in the rest of the animal kingdom). The stroma is composed of interstitial cells and connective tissue.
At puberty, and at the end of reproductive life, many cycles are anovulatory: anovulatory cycles, due to increased FSH stimulation, tend to release more oestrogen and testosterone from the ovary and are usually shorter. At menarche therefore ovarian function may be more vulnerable to external factors which alter the delicate homeostasis between midbrain and ovarian hormone production.
Ovarian scanning
The conventional method of scanning the ovary is by ultrasound, either through the abdomen (which can be inaccurate, particularly in the obese) or transvaginally, which is more accurate but more intrusive and may still miss structures outside the cone of sound. Ultrasound has the advantage that it can be frequently repeated, so that changes in ovarian structure can be closely monitored (and reveal that the ovary is a dynamic and not a static structure). Experienced operators can make mostly reliable judgments about the nature of the content of ovarian cysts and can estimate the volume of the ovary, its cysts or its stroma. Full interpretation of a scan requires a great deal of experience. Almost all the literature on the prevelance of ovarian cysts is derived from ultrasound studies.
MRI scanning of the pelvis has also been used to study the structure of the ovary and indeed may well be more accurate 11 . It is more costly than ultrasound, and this factor alone precludes it's repetitive use so that it only provides a snapshot of ovarian structure at a moment in time. It is likely to be more widely used in the future. Further experience of the method will increase the accuracy of the prediction of the contents of ovarian cysts. A normal MRI scan of the ovaries, with the expected number and size of cysts is shown in Fig. 1 . MRI, because it is cross sectional and three dimensional, can provide very accurate estimates of size and volume both of the ovary and its cysts.
A scan of the ovary (either good quality ultrasound or MRI) can reveal:
(1) a normal sized ovary, with the expected number of cysts of normal size (i.e. pre-ovulatory, ovulatory and atretic cysts;
(2) a normal sized ovary with more than the expected number of cysts (but of normal size)-usually assumed to be an increased number of atretic cysts; (3) or a normal sized ovary with larger than usual cysts; (4) or an ovary with stromal enlargement in addition to an increased number (and/or size) of cysts (Fig. 2) . The meaning of these findings is open to different interpretations.
The 'cysts' are of course, follicles. Referring to them as cysts has lead to much confusion.
Polycystic ovaries and the PCOS
In 1937 Stein and Leventhal, two American gynaecologists, published a paper 12 describing a group of women who were hirsute, obese, had severe menstrual irregularities and were infertile. At laparotomy they were found to have enlarged ovaries with multiple large cysts. Resection of wedges of their enlarged ovaries returned menstruation to normal and restored fertility, at least for a while. At this time, modern endocrinology was in its infancy: later investigation of this initially structural syndrome showed that such women had high testosterone and luteinizing hormone levels. The concept of the PCOS therefore changed to encompass these endocrine findings and was thought to be associated with obesity, hirsutism and infertility. Later it was recognised that women with this syndrome were at increased risk of endometrial carcinoma (due to irregular menstruation) and possibly of ovarian and breast carcinoma and of the early development of diabetes and atherosclerotic disease.
Developments in ultrasound scanning showed that many women, even those of normal weight with normal menstruation and with no measurable endocrine change and without enlarged ovaries, had more cysts in their ovaries than was usual: these have also been confusingly called 'polycystic'. The meaning of this finding is controversial. It is so common that many authorities do not regard it as abnormal and rightly prefer the term 'polyfollicular ovary' to 'polycystic ovary' 13 . If young women, with entirely normal menstrual cycles, are examined by ultrasound the incidence of polyfollicular ovaries is about 8-10% 14 .
There is also a dichotomy between European and United States practice. The diagnosis of the PCOS in the States is made without recourse to ultrasound scanning: (indeed some authorities warn vigorously against this practice 10 ).
Most authorities nowadays draw a distinction between women who merely have polyfollicular ovaries but no hormonal changes and those women that have polyfollicular ovaries (often with somewhat enlarged stroma) who do have the hormonal changes consistent with the so-called PCOS (raised testosterone &/or luteinizing hormone levels or a reversed FSH/LH ratio). Such women are often (but not invariably) overweight, and hirsute with menstrual irregularity: but some women of normal weight who are not hirsute can also have it. In Europe the ovary is considered polycystic if it contains, on ultrasound examination, at least 10 cysts between 2 and 8 mm in diameter, particularly if associated with an increase in ovarian stroma 15 . The prevalence of the PCOS has been estimated as between 5% and 26% of the female population in the United Kingdom, depending on the definition used 16 . The aetiology of the PCOS is controversial 17 . The primary dysfunction at various times has been suggested to be in the hypothalamic/pituitary axis, in the adrenal or the ovary or that all the clinical manifestations are due to hyperinsulinaemia.
There is increasing evidence for a major genetic component for polycystic ovaries and the PCOS. Strong familial clustering has been shown with a high prevalence amongst siblings 18, 19 . Although an autosomal dominant mode of inheritance has been suggested because of the heterogenicity of the PCOS it is most likely to be due to a complex trait in which a small number of genes interact with external environmental factors and other genetic factors, thus affecting the expression of the syndrome 19 .
Genetic studies have shown possible abnormalities in the regulation of the expression of the insulin gene and abnormalities in the genes involved in steroidogenesis 16, 19 . The possible involvement of the insulin gene adds to the importance of the role of hyperinsulinaemia, secondary to insulin resistance, in the PCOS, which is now thought by many to be the key to the pathogenesis of the syndrome 16 . This view is supported by a study showing that 82% of women with Type II diabetes (a condition also known to be associated with insulin resistance) had polycystic ovaries on ultrasound and 52% had symptoms of the PCOS 20 . Insulin resistance is most evident in overweight patients 18 although insulin concentration has still been shown to be higher in both lean and obese patients with the PCOS than in control populations 20 .
Insulin affects the ovary, in combination with an elevated luteinizing hormone concentration, by causing thecal cell hyperplasia, increased androgen levels, arrested follicular development and, thus, anovulation with menstrual disturbance 19 . This disturbance of normal ovarian function results in multiple small cysts in the ovaries, which mostly contain potentially viable oocytes within dysfunctional follicles 17 . Insulin also acts on the liver to inhibit production of both sex hormone binding globulin (leading to increased free testosterone) and insulin-like growth factor 1 binding protein (causing increased free insulin-like growth factor 1 and enhancing further ovarian androgen production) 19 . As well as hyperinsulinaemia, other factors may affect the expression of the PCOS. Weight gain worsens symptoms: feedback from the polycystic ovary to the pituitary and the hypothalamus seems to play a part in the syndrome as it is disturbed by abnormalities in the secretion of ovarian steroidal and non-steroidal hormones 17 .
The pathogenesis of the PCOS is probably multifactorial and not purely due to hyperinsulinaemia. Indeed Speroff, Glass and Kase, 1999 10 make powerful arguments that 'the characteristic polycystic ovary emerges when a state of anovulation persists for any length of time. . . because there are many causes of anovulation, there are many causes of polycystic ovaries. A similar clinical picture and ovarian condition can reflect any of the dysfunctional states discussed above. In other words the polycystic ovary is the result of a functional derangement, not a specific central or local defect'. There is no doubt, however, that a raised insulin level, often due to insulin resistance, does seem to be an important aetiological factor in some of the characteristics of the PCOS.
Although most authorities do make a clear distinction between merely possessing poly-follicular ovaries and having the PCOS it is currently uncertain whether women who have polyfollicular ovaries, but no present evidence of the hormonal changes that go with the PCOS, will eventually develop the syndrome: does possession of polyfollicular ovaries mark an early stage of the full syndrome, a vulnerability to it, or are they, as some think, 13 unconnected? What is clear, however, is that what was initially seen as a structural syndrome (indeed in the early days the cysts were surgically treated or wedges of ovarian tissue were removed 12 -which resulted in temporary improvement due to excision of androgen secreting tissue of the ovary), is now seen as an hormonal and metabolic syndrome 19 , with the structural changes now considered to be secondary.
The time of first expression of the PCOS may also be important in discussing its pathogenesis. Polyfollicular ovaries can be detected in early childhood, before puberty, and the onset of the syndrome may occur in late childhood. Since many of the metabolic and endocrine features of the disorder are similar to those that naturally occur during puberty (for example insulin resistance, increased testosterone and luteinizing hormone levels and anovulatory cycles) it may be that females genetically predisposed to the PCOS fail to resume normal insulin sensitivity and thus continue to express features usually confined to puberty itself 19 .
This may be important to the putative relationship between sodium valproate and the PCOS.
The PCOS and epilepsy
There is some evidence to suggest that menstrual disorders, polyfollicular ovaries and the PCOS (and, therefore, relative infertility), may be more common in women with epilepsy than in the general population 6 . It has to be said that the evidence for this is somewhat shaky, based on small populations and probably conflated results, and some population studies of women suggest that these abnormalities may be just as common in women who do not have epilepsy.
Further large-scale studies in unselected populations of women with epilepsy are needed to resolve whether this relationship exists or not.
If women with epilepsy do have an increased prevalence of menstrual disorders and the PCOS, it may be that the epilepsy itself is implicated. Women with epilepsy, even those not on active treatment have been shown to have an altered LH pulse frequency 21, 22 . It is possible that epilepsy interferes with the gonadotrophic releasing pulse generator (i.e. it increases gondadotrophin releasing hormone pulse frequency) which affects ovarian function by inhibiting ovulation producing poly-follicular ovaries and later the PCOS 21, 22 . It has been suggested that this might be more common in women with partial seizures as opposed to primary generalised epilepsy 21 , but an increased occurrence of the PCOS has also been reported in women with primary generalised epilepsy 22 .
An alternative theory to explain the probable increased frequency of menstrual disorders and the PCOS in women with epilepsy is that a primitive neuro-transmitter dysfunction is present which gives rise to both the seizure disorder and abnormal gonadotrophic releasing hormone secretion, in turn producing polyfollicular ovaries and the PCOS 22 .
There is evidence that anovulatory cycles may be associated with more frequent seizures. If a woman has the PCOS her anovulatory cycles expose the brain to higher levels of oestrogen but without cyclic progesterone release, producing a potential worsening of seizure control in women with both the PCOS and epilepsy (progesterone is potentially anticonvulsant, oestrogen proconvulsant) 23 .
The issue is still not resolved whether it is a particular form of epilepsy, or a separate genetic predisposition for polycystic ovaries and the PCOS or a combination of both that produces the irregular gonadotrophin releasing hormone pulsatile secretion (which leads to irregular luteinizing hormone secretion) and thus the reproductive endocrine disorders in women with epilepsy 6, 22 . It may be that luteinizing hormone hyperpulsive activity, which is a condition associated with epilepsy, makes women with epilepsy, possibly already genetically predisposed to the PCOS, more likely to develop symptoms of it than if they had not suffered with epilepsy. It could also be that women with polyfollicular ovaries or the PCOS are more prone to epilepsy itself (as such women are to diabetes) and there is a shared genetic predisposition to both. The science of the molecular genetics of epilepsy is making rapid strides and may possibly provide an answer to this question in due course.
Polycystic ovaries, PCOS, sodium valproate and other anticonvulsants
Although women with epilepsy may already have a higher instance of the PCOS and polyfollicular ovaries, it has been suggested that treatment with sodium valproate increases this risk further [7] [8] [9] . This is a controversial view: others have produced evidence to suggest that sodium valproate is not significantly associated with polyfollicular ovaries or the PCOS 24, 25 .
Isojärvi and his colleagues [7] [8] [9] showed that, in the population of women that they studied, polycystic ovaries or elevated testosterone levels (hyperandrogenism) were found in the majority (64%) of women receiving valproate as therapy for their epilepsy, but in women receiving medication other than valproate, they found that the frequency of polycystic ovaries and of hyperandrogenism did not differ from that of normal women.
These studies have been strongly criticized 26 . It has been suggested that Isojärvi and colleagues muddled the definition of polycystic ovaries, so that women who only had polyfollicular ovaries were joined with those that had raised androgen levels with or without polyfollicular ovaries. It is difficult to determine from the publications if some women from the first series 7 were included (or not) in the second series 8 . The decline in the number of cysts reported after the substitution of lamotrigine for valproate is not statistically significant and the population studied was a very selected one 9 . The women in the study may have been unintentionally selected for their obesity since their original body mass index (before treatment with valproate) is not stated: were they always obese or did they gain weight on valproate? Was there any evidence of similar weight gain in the control group? It is also not clear whether the hormone measurements were taken at the right point in the menstrual cycle, and at the same time of day (there are both cyclical and diurnal changes in hormone levels).
These criticisms are important, because Isojärvi and his colleagues ascribe the increased incidence of polycystic ovaries and the PCOS in women taking valproate to the weight gain that may go with taking valproate 8 (though not all the patients in their series with the PCOS were overweight). Valproate increases insulin levels, possibly due to its effect on insulin resistance 8 : which may lead to the hormonal and structural ovarian changes characteristic of the PCOS.
These studies, although widely quoted, are seriously flawed. But they do raise important questions, since the PCOS has important consequences: relative infertility, possible later diabetes and malignancy. If an anticonvulsant is 'causing' such a syndrome it would be serious. How might this association be better proven (or disproved)?
There are two possible solutions. The first would be to study women at the start of their epilepsy, before and after they start antiepileptic treatment in monotherapy, and follow them up monitoring both ovarian structure and hormonal profiles. Such a study is underway in the UK 26 but may have recruitment difficulties: ovarian structure is being assessed by abdominal ultrasound which may not be particularly reliable. But it is a study worth supporting.
The second solution is to examine groups of women who have only ever taken one antiepileptic drug in monotherapy (and who have the same type of epilepsy) and examine their body mass index, ovarian structure and hormonal profile. Such a study is being carried out in our department (using ovarian MRI scanning). It is still ongoing but early results 27 suggest in a group of young women taking either valproate, lamotrigine or carbamazepine in exclusive monotherapy for primary generalised epilepsy that:
(A) There is no difference in body mass index between the three groups.
(B) The prevalence of polyfollicular/polycystic ovaries is high (59%).
(C) The prevalence of polyfollicular/polycystic ovaries is the same in the three groups.
(D) In the women with polyfollicular/polycystic ovaries it is only in the group taking valproate that raised testosterone/ and or luteinizing hormone levels are found.
(E) Substitution of lamotrigine for valproate leads to an immediate drop in testosterone and/or luteinizing hormone level, before the valproate is withdrawn.
(F) After valproate withdrawal there is some evidence of reduction in ovarian volume and cyst size.
(G) The 'valproate effect' may be age specific, more likely to occur in those women taking valproate at around puberty.
These results are interesting and, if confirmed in a larger series (using a control population) suggest that Isojärvi and his colleagues were partly right, but also partly wrong. Our study so far suggests that valproate does not cause polyfollicular/polycystic ovaries in women with epilepsy: they are already there and are presumably due to the epilepsy. Valproate, unlike the other two antiepileptic drugs, may push women (already pre-disposed by having polyfollicular ovaries) down the metabolic pathway towards the PCOS (possibly by raising insulin resistance) but this effect is reversible. The other two drugs seem protective against this effect, carbamazepine possibly by its enzyme inducing effect reducing levels of unbound testosterone: the mechanism of lamotrigine protection, since the drug is not enzyme inducing, is unknown.
These findings have changed our policy toward female adolescents coming into our care: if they are on valproate monotherapy we investigate ovarian structure and function. If they have polyfollicular ovaries (or have evidence of the PCOS) we withdraw the valproate and substitute another appropriate drug: if ovaries and hormones are normal and the patient is seizure free they can stay on the valproate for a while (but it is withdrawn later, before they wish to conceive).
In evaluating conflicting papers on the effect of valproate on ovarian structure and function it is important to ask whether the patients are on valproate monotherapy and always have been or not and at what age they started to take valproate. Women taking valproate plus an enzyme inducing drug may not show the valproate ovary effect, and nor, probably, will women starting valproate later in life: we have shown 27 that women taking a mixture of lamotrigine and valproate do not show this effect. It is probably more likely to be seen in girls taking valproate before or during puberty whose ovarian function may be already vulnerable.
